|
|
|
| Effect of Labellol Combined with Enoxaparin on Hypertensive Patients During Pregnancy |
| FU Hong |
| The Maternal and Children Health Care Hospital of Zigong, Zigong, Sichuan 643000,China |
|
|
|
|
Abstract 【Objective】To investigate the effects of labelore combined with enoxaparin on blood pressure level and its safety in patients with hypertensive diseases in pregnancy. 【Methods】 One hundred and two patients with gestational hypertension admitted to our hospital from June 2017 to June 2018 were randomly divided into two groups. The control group was treated with oral labetalol tablets, and the study group was treated with labetalol combined with enoxaparin. The clinical therapeutic effect, blood pressure level, 24 h urinary protein level, blood lipid level before and after treatment, and the incidence of adverse reactions and severe adverse pregnancy outcomes were compared between the two groups. 【Results】The total effective rate was 94.1% (48/51) in the observation group, which was significantly higher than 78.4% (40/51) in the control group. The difference was statistically significant (χ2=7.318,P<0.05). Before treatment, there was no significant difference in blood pressure and 24-hour urinary protein between the two groups (P>0.05); after treatment, the above indicators in both groups decreased significantly compared with before treatment (P<0.05), and the observation group decreased more significantly (P<0.05). Before treatment, there was no significant difference in blood lipid levels between the two groups (P>0.05); after treatment, the levels of LDL-C, TC and TG in the two groups were significantly lower than those before treatment, and the levels of HDL-C were significantly higher than those before treatment, and the observation group was significantly better than those before treatment. The control group (P<0.05). Compared with the control group, the incidence of adverse pregnancy outcomes such as premature delivery, postpartum hemorrhage, fetal distress and neonatal asphyxia in the observation group was significantly lower than that in the control group, and the difference was statistically significant (P<0.05). The total incidence of adverse reactions was 39.22% (20/51) in the observation group and 35.29% (18/51) in the control group. There was no significant difference between the two groups (P>0.05). The adverse reactions in the two groups were mild and improved by symptomatic treatment without affecting the follow-up treatment.【Conclusion】Labellol combined with enoxaparin in the treatment of pregnancy-induced hypertension can significantly reduce blood pressure and 24-hour urinary protein levels, reduce the incidence of adverse pregnancy outcomes, and has high safety, which is worthy of clinical application.
|
|
Received: 06 November 2018
|
|
|
|
|
|
[1] 乐杰.《妇产科学》[M].第7版.北京:人民卫生出版社,2008:92-99.
[2] 牛影,徐叶清,郝加虎, 等.马鞍山市妇女孕前体质指数和孕期增重与妊娠期高血压疾病的队列研究[J].卫生研究,2016,45(2):205-210.
[3] 马菁雯. 低分子肝素干预对妊娠期高血压疾病母体不良妊娠结局的影响[J].中国妇幼保健, 2017,32(6):1161-1164.
[4] 赵倩,高岚.银杏达莫注射液联合盐酸拉贝洛尔对妊娠期高血压疾病孕妇血清FIB、ET-1、NO水平变化及母婴结局的影响[J].中国妇幼保健,2018,33(8):1701-1703.
[5] 王琴娟,徐英.甲基多巴联合拉贝洛尔治疗妊娠期高血压疾病的疗效及安全性分析[J].中国妇幼保健,2017,32(1):23-25.
[6] 贾辉.大港油田女职工妊娠期高血压疾病的危险因素及患病率调查[J].中国妇幼保健,2017,32(11):2445-2447.
[7] 赵洁.硫酸镁治疗妊娠期高血压疾病的效果及其影响[J].中外医疗,2017,36(6):125-126.
[8] 阮琦,区淑珍.甲基多巴联合拉贝洛尔治疗妊娠高血压的疗效观察及其机制探讨[J].岭南心血管病杂志,2016,22(4):446-448.
[9] 吴丽琴,孙玉娟,苏翠珍,等.低分子量肝素钠注射液联合硫酸镁注射液和拉贝洛尔片治疗重度妊娠期高血压综合征的临床研究[J].中国临床药理学杂志,2019,35(3):216-219. |
|
|
|
2019, Vol. 36 
